AREDS2 supplementation

AREDS2 supplementation has been studied in 2 papers since 2026: none in people yet, 2 reviews; 2 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 19, 2026: “The Environmental Exposome and Age-Related Macular Degeneration: Oxidative Stress as a Molecular Link”.

Intervention

2 papers study it2 findingsUpdated

1 new paper in 30 daysSee all 2 papers on AREDS2 supplementation

What did studies of AREDS2 supplementation find?

1

Studies of AREDS2 supplementation measured one outcome, lung cancer.

Lung cancer

no changein humans1

1 study
  1. AREDS2 supplementation showed no clear effect on lung cancer in smokers.

    “without increasing the risk of lung cancer in smokers”

    Reviewin smokers

    AREDS2 as a Retinal Protective Strategy Against Aging: A Literature Review from a Geroscience Perspective

    Cermin Dunia Kedokteran

More on Lung cancer

What is AREDS2 supplementation linked with?

1

Studies link AREDS2 supplementation with age-related macular degeneration progression.

Age-related macular degeneration progression

downin humans1−18% risk

1 study
  1. AREDS2 supplementation lowers the risk of age-related macular degeneration progression in humans (18% reduction in risk).

    “has been shown to reduce the risk of AMD progression by 18%”

    Reviewreplacing beta-carotene with lutein and zeaxanthin

    AREDS2 as a Retinal Protective Strategy Against Aging: A Literature Review from a Geroscience Perspective

    Cermin Dunia Kedokteran

More on Age-related macular degeneration progression

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 1Nov 2026: 02 papers in 12 months